These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 24918318)

  • 41. Infliximab reintroduction is not associated to a higher rate of immune-related adverse effects in patients with inflammatory bowel disease initially treated with a three-infusion induction regimen.
    Domènech E; Zabana Y; Mañosa M; Garcia-Planella E; Cabré E; Gassull MA
    J Clin Gastroenterol; 2010 Jan; 44(1):34-7. PubMed ID: 19417683
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Infliximab for the treatment of psoriasis in the U.K.: 9 years' experience of infusion reactions at a single centre.
    Wee JS; Petrof G; Jackson K; Barker JN; Smith CH
    Br J Dermatol; 2012 Aug; 167(2):411-6. PubMed ID: 22404545
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Psoriasis induced by infliximab].
    Fernandes IC; Torres T; Sanches M; Velho G; Lago P; Selores M
    Acta Med Port; 2011 Dec; 24 Suppl 3():709-12. PubMed ID: 22856418
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped.
    Louis E; Mary JY; Vernier-Massouille G; Grimaud JC; Bouhnik Y; Laharie D; Dupas JL; Pillant H; Picon L; Veyrac M; Flamant M; Savoye G; Jian R; Devos M; Porcher R; Paintaud G; Piver E; Colombel JF; Lemann M;
    Gastroenterology; 2012 Jan; 142(1):63-70.e5; quiz e31. PubMed ID: 21945953
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Evaluation of Rapid vs Standard Infliximab Infusions in the Pediatric Population.
    Rozette NA; Hellauer CM; McKee C; Vazifedan T; Gabriel CA; Dice JE; Yokois NU
    Inflamm Bowel Dis; 2018 Aug; 24(9):2007-2014. PubMed ID: 29788416
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cutaneous adverse reaction to infliximab: report of psoriasis developing in 3 patients.
    Severs GA; Lawlor TH; Purcell SM; Adler DJ; Thompson R
    Cutis; 2007 Sep; 80(3):231-7. PubMed ID: 17956013
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Long-term Efficacy, Safety, and Immunogenicity of Biosimilar Infliximab After One Year in a Prospective Nationwide Cohort.
    Gonczi L; Gecse KB; Vegh Z; Kurti Z; Rutka M; Farkas K; Golovics PA; Lovasz BD; Banai J; Bene L; Gasztonyi B; Kristof T; Lakatos L; Miheller P; Nagy F; Palatka K; Papp M; Patai A; Salamon A; Szamosi T; Szepes Z; Toth GT; Vincze A; Szalay B; Molnar T; Lakatos PL
    Inflamm Bowel Dis; 2017 Nov; 23(11):1908-1915. PubMed ID: 28922253
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study.
    Fidder H; Schnitzler F; Ferrante M; Noman M; Katsanos K; Segaert S; Henckaerts L; Van Assche G; Vermeire S; Rutgeerts P
    Gut; 2009 Apr; 58(4):501-8. PubMed ID: 18832524
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Infliximab dependency in pediatric Crohn's disease: long-term follow-up of an unselected cohort.
    de Ridder L; Rings EH; Damen GM; Kneepkens CM; Schweizer JJ; Kokke FT; Benninga MA; Norbruis OF; Hoekstra JH; Gijsbers CF; Escher JC
    Inflamm Bowel Dis; 2008 Mar; 14(3):353-8. PubMed ID: 18069674
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Serious events with infliximab in patients with inflammatory bowel disease: a 9-year cohort study in the Netherlands.
    de Vries HS; van Oijen MG; de Jong DJ
    Drug Saf; 2008; 31(12):1135-44. PubMed ID: 19026030
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Infliximab-induced psoriasis during therapy for Crohn's disease.
    Steinwurz F; Denadai R; Saad-Hossne R; Queiroz ML; Teixeira FV; Romiti R
    J Crohns Colitis; 2012 Jun; 6(5):610-6. PubMed ID: 22398095
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease.
    Miehsler W; Novacek G; Wenzl H; Vogelsang H; Knoflach P; Kaser A; Dejaco C; Petritsch W; Kapitan M; Maier H; Graninger W; Tilg H; Reinisch W;
    J Crohns Colitis; 2010 Sep; 4(3):221-56. PubMed ID: 21122513
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Distinct Thresholds of Infliximab Trough Level Are Associated with Different Therapeutic Outcomes in Patients with Inflammatory Bowel Disease: A Prospective Observational Study.
    Roblin X; Boschetti G; Duru G; Williet N; Deltedesco E; Phelip JM; Peyrin-Biroulet L; Nancey S; Flourié B; Paul S
    Inflamm Bowel Dis; 2017 Nov; 23(11):2048-2053. PubMed ID: 28945636
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Meta-analysis: rapid infliximab infusions are safe.
    Neef HC; Riebschleger MP; Adler J
    Aliment Pharmacol Ther; 2013 Aug; 38(4):365-76. PubMed ID: 23815183
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease.
    Kugathasan S; Werlin SL; Martinez A; Rivera MT; Heikenen JB; Binion DG
    Am J Gastroenterol; 2000 Nov; 95(11):3189-94. PubMed ID: 11095340
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cumulative incidence of, risk factors for, and outcome of dermatological complications of anti-TNF therapy in inflammatory bowel disease: a 14-year experience.
    Fréling E; Baumann C; Cuny JF; Bigard MA; Schmutz JL; Barbaud A; Peyrin-Biroulet L
    Am J Gastroenterol; 2015 Aug; 110(8):1186-96. PubMed ID: 26195181
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Anti-TNFα antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease: an Irish Cohort Study.
    Kirthi Jeyarajah S; Tobin AM; Hussey M; Scaldaferri F; McNamara D
    QJM; 2017 Jun; 110(6):379-382. PubMed ID: 28069913
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Paradoxical psoriasiform reactions of anti-tumour necrosis factor therapy in inflammatory bowel disease patients.
    Peer FC; Miller A; Pavli P; Subramaniam K
    Intern Med J; 2017 Dec; 47(12):1445-1448. PubMed ID: 29224199
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Psoriasis and psoriatic arthritis induced in a patient treated with infliximab for Crohn's disease.
    Tichy M; Tichy M; Kopova R; Sternbersky J; Ditrichova D
    J Dermatolog Treat; 2012 Jun; 23(3):208-11. PubMed ID: 21254868
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Dermatological adverse reactions during anti-TNF treatments: focus on inflammatory bowel disease.
    Mocci G; Marzo M; Papa A; Armuzzi A; Guidi L
    J Crohns Colitis; 2013 Nov; 7(10):769-79. PubMed ID: 23453887
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.